Safety testing of cosmetic products by patch test

Completed

Conditions: Adult subjects in the age group of 18 years to 55 years (both inclusive) will be selected

Brief Summary: Objective :The objective of this study is to evaluate the dermatological safety of the investigational products on healthy human subjects with sensitive skin.Primary irritation patch test is used widely for the evaluation of safety of cosmetics in humans.

Sample Size :Thirty Five (male and female, in a nearly ratio of 1:1) adult subjects in the age group of 18 years to 55 years (both inclusive)

Primary skin irritation results from reversible inflammatory changes in the skin following the application of a test substance.

By this test, irritation potential of a substance is assessed by a single application of patch under complete occlusion for 24 hrs and is done as per BIS standard (IS4011:1997) &IS 13424:2001

Recruitment & Eligibility

Inclusion Criteria

Healthy male and female subjects in the age group of 18-55 years (both age inclusive) 2.
Subjects in good general health 3.
Subjects with Fitzpatrick skin type III to V 4.Subjects scoring greater than 30 for Section 2- Sensitive v/s Resistant skin in modified Dr. Baumannâ€™s skin type questionnaire 5.Subject identified to have sensitive skin basis dermatologistâ€™s assessment of skin with fine texture and closeness of blood vessels to the surface 6.Subjects willing to give a voluntary written informed consent 7.
Subjects having not participated in a similar investigation in the past eight weeks 9.
Subjects willing to come for regular follow up visits 10.
Subjects ready to follow instructions during the study period 11.
Subjects without any open wounds, cuts, abrasions, irritation symptoms.

Exclusion Criteria

Subjects with a present condition of allergic response to any cosmetic product 2.
Subjects under chronic medication (e.g. Antihistamines, Antifungals, Corticosteroids, topical Steroids, etc.) that might influence the outcome of the study 3.
Subjects who are pregnant or nursing (as confirmed by Urine pregnancy test for the determination of Pregnancy) 4.
Subjects with cutaneous disease that could interfere with the study results 5.
Subjects with chronic illness that may influence the cutaneous state or any other illness including Diabetes, liver disease, HIV or any other serious medical illness 6.
Subjects participating in any other cosmetic or therapeutic trial.

Primary Outcome Measures

Name	Time	Method
Safety assessment of investigational products for irritation potential using Draize scale	Draize scoring to be done at 0 hr, 24 hrs and day 7 of patch removal

Secondary Outcome Measures

Name	Time	Method
N/A	N/A

Locations (1): CIDP Biotech India Pvt. Ltd.
🇮🇳
Delhi, DELHI, India
CIDP Biotech India Pvt. Ltd.
🇮🇳Delhi, DELHI, India
Dr Annie Jain MD
Principal investigator
01140793385
a.jain@cidp-cro.com